Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers

Abstract

We hypothesize that smokers with the null genotype for GSTM1 (GSTM1- 0), who thus lack the detoxification enzyme glutathione S-transferase μ1, develop atherosclerosis at an increased rate compared to smokers with the positive genotype (GSTM1- 1). We used data from a 2-year randomized placebo-controlled trial on the effect of vitamin E on atherosclerosis among 189 male smokers. Progression of atherosclerosis was measured by 2-year change of the common carotid intima media thickness (CCA-IMT) as measured by B-mode ultrasonography. The frequency of GSTM1- 0 genotype was 0.5 in both the placebo and the vitamin E group. Smokers with GSTM1- 0 genotype had a tendency to higher baseline CCA-IMT values than those with GSTM1 -1 (0.97 versus 0.92 mm, P=0.09). Within the placebo group, more CCA-IMT progression was found for smokers with the GSTM1- 0 than for smokers with the GSTM1- 1 genotype after adjustment for baseline IMT and major CVD risk factors (0.050 versus −0.002 mm, P=0.046). In the vitamin E group no effect of GSTM1 genotype on atherosclerosis progression was found. Overall, smokers with GSTM1- 0 genotype had a higher mean 2-year progression compared to those with GSTM1 -1 as shown by a difference in increase of 0.042 mm (95% CI 0.006; 0.078, P=0.02). In conclusion, our data suggest that smokers lacking the detoxifying enzyme GST μ1 develop progression of atherosclerosis at an increased rate.